Back to Browse Journals » The Application of Clinical Genetics » Volume 5

The genetics of neuroendocrine prostate cancers: a review of current and emerging candidates

Authors Ather MH, Siddiqui T

Published Date November 2012 Volume 2012:5 Pages 105—110

DOI http://dx.doi.org/10.2147/TACG.S28881

Received 10 August 2012, Accepted 2 October 2012, Published 8 November 2012

M Hammad Ather,1 Tahmeena Siddiqui2

1Dept of Surgery, Aga Khan University, 2Karachi Medical and Dental College, Karachi, Pakistan

Abstract: Prostate cancer (PC) displays a strong familial link and genetic factors; genes regulating inflammation may have a pivotal role in the disease. Epigenetic changes control chromosomal integrity, gene functions, and, ultimately, carcinogenesis. The most widely studied epigenetic event in PC is aberrant DNA methylation (hypo- and hypermethylation); besides this, chromatin remodeling and micro RNA (miRNA) are other studied alterations in PC. These all lead to genomic instability and inappropriate gene expression. Causative dysfunction of histone modifying enzymes results in generic and locus-specific changes in chromatin remodeling. miRNA deregulation also contributes to prostate carcinogenesis, including interference with androgen-receptor signaling and apoptosis. These epigenetic alterations have the potential to act as biomarkers for PC for screening and diagnosis as well as prognosis and follow-up. The variable biological potential for a newly diagnosed PC is one of the biggest challenges. The other major clinical problem is in the management of castration-resistant PC. Neuroendocrine (NE) differentiation is one of the putative explanations for the development of castration-resistant disease. Most advanced and poorly differentiated cancer does not produce prostate-specific antigen (PSA) in response to disease progression. Circulating and tissue biomarkers like chromogranin A (CgA) thus become important tools. There is the potential to use various genetic and epigenetic alterations and NE differentiation as therapeutic targets in the management of PC. However, we are still some distance from developing clinically effective tools. Valuable insights into the nature of NE differentiation in PC have been gained in the last decades, but additional understanding of its pathogenetic mechanisms is needed. This will help in devising novel therapeutic strategies to develop targeted therapies. CgA has the potential to become an important marker of advanced castration-resistant PC in cases where prostate-specific antigen can no longer be relied upon. Aberrant androgen-receptor signaling at various levels provides evidence of the importance of this pathway for the development of castration-resistant PC. Many epigenetic influences – in particular, the role of changing miRNA expression – provide valuable insights. Currently, massive sequencing efforts are underway to define important somatic genetic alterations (amplifications, deletions, point mutations, translocations) in PC, and these alterations hold great promise as prognostic markers and for predicting response to therapy.

Keywords: prostate cancer, epigenetic, genetic, neuroendocrine differentiation

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Genetic basis of cohesinopathies

Barbero JL

The Application of Clinical Genetics 2013, 6:15-23

Published Date: 1 May 2013

Gene mutations in cardiac arrhythmias: a review of recent evidence in ion channelopathies

Hsiao PY, Tien HC, Lo CP, Juang JM, Wang YH, Sung RJ

The Application of Clinical Genetics 2013, 6:1-13

Published Date: 18 January 2013

Genetics of hearing loss: focus on DFNA2

Dominguez LM, Dodson KM

The Application of Clinical Genetics 2012, 5:97-104

Published Date: 18 October 2012

The Application of Clinical Genetics

Maurer MH

The Application of Clinical Genetics 2012, 5:19-20

Published Date: 23 February 2012

The genomics and genetics of ankylosing spondylitis

Kenna TJ, Davidson SI, Thomas GP

Advances in Genomics and Genetics 2011, 1:9-25

Published Date: 16 December 2011

Inherited and acquired alterations in development of breast cancer

Rizzolo P, Silvestri V, Falchetti M, Ottini L

The Application of Clinical Genetics 2011, 4:145-158

Published Date: 14 November 2011

GSTM1 null genotype in COPD and lung cancer: evidence of a modifier or confounding effect?

Young RP, Hopkins RJ, Hay BA, Gamble GD

The Application of Clinical Genetics 2011, 4:137-144

Published Date: 13 September 2011

Genetic basis of Parkinson's disease: inheritance, penetrance, and expression

Schulte C, Gasser T

The Application of Clinical Genetics 2011, 4:67-80

Published Date: 1 June 2011

Prognostic role of neuroendocrine differentiation in prostate cancer, putting together the pieces of the puzzle

Alfredo Berruti, Francesca Vignani, Lucianna Russo, et al

Research and Reports in Urology 2010, 2:109-124

Published Date: 23 July 2010